FXN and Friedreich ataxia: This is because FA patients’ cells express frataxin at much lower levels (5–30% according to the GAA repeats length variability (Gellera et al., 2007), and it is acknowledged in the FA community that neither gene therapy nor small molecules approaches will be able to increase frataxin at healthy control levels.